Sensus Healthcare, Inc.
Business
Sensus Healthcare is a medical device company that manufactures and markets superficial radiation therapy (SRT) systems for treating non-melanoma skin cancer and keloid scars. The company offers three SRT device models (SRT-100, SRT-100+, SRT-100 Vision), along with service programs including the Sentinel maintenance program and the Fair Deal Agreement recurring-revenue model. Sensus sells its systems to dermatology practices and radiation oncology clinics in the United States and internationally across 21 countries, and provides consumables, financing services, and cloud-based software connectivity solutions.
Summary from 10-K filed 2026-03-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 27 | 42 | 24 | — | — | |
| Cost of sales | 16 | 17 | 10 | 15 | 10 | |
| Gross profit | 12 | 24 | 14 | 30 | 17 | |
| General and administrative | 8 | 7 | 5 | — | — | |
| Selling and marketing | 7 | 5 | 6 | 6 | 5 | |
| Research and development | 8 | 4 | 4 | 3 | 3 | |
| Total operating expenses | 22 | 16 | 14 | 15 | 13 | |
| (Loss) income from operations | −10 | 8 | −382,000 | 15 | 4 | |
| Interest income, net | 683,000 | 932,000 | — | — | — | |
| Other income, net | 683,000 | 932,000 | 1 | 13 | — | |
| (Loss) income before income taxes | −10 | 9 | 652,000 | 28 | 4 | |
| (Benefit from) provision for income taxes | −2 | 2 | 167,000 | 4 | — | |
| Net (loss) income | −8 | 7 | 485,000 | 24 | 4 | |
| Net (loss) income per share - basic | −0.47 | 0.41 | 0.03 | 1.47 | 0.25 | |
| Net (loss) income per share - diluted | −0.47 | 0.41 | 0.03 | 1.46 | 0.25 | |
| Weighted average number of shares used in computing net (loss) income per share - basic | 16 | 16 | 16 | 16 | 16 | |
| Weighted average number of shares used in computing net (loss) income per share - diluted | 16 | 16 | 16 | 17 | 17 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 22 | 22 | 23 | 26 | 15 | |
| Accounts receivable, net | 6 | 20 | 11 | 17 | 12 | |
| Inventories | 15 | 10 | 12 | 4 | 2 | |
| Prepaid inventory | 2 | 3 | 3 | 6 | — | |
| Other current assets | 2 | 2 | 888,000 | 660,000 | — | |
| Total current assets | 46 | 57 | 50 | 53 | 31 | |
| Property and equipment, net | 2 | 2 | 464,000 | 243,000 | 605,000 | |
| Deferred tax assets, net | 4 | 2 | 2 | 2 | — | |
| Operating lease right-of-use assets, net | 452,000 | 581,000 | 774,000 | 996,000 | 169,000 | |
| Other noncurrent assets | 640,000 | 652,000 | 804,000 | 542,000 | — | |
| Total assets | 53 | 62 | 54 | 57 | 32 | |
| Accounts payable and accrued expenses | 3 | 5 | 3 | 6 | 4 | |
| Product warranties | 275,000 | 329,000 | 538,000 | 403,000 | 508,000 | |
| Operating lease liabilities, current portion | 262,000 | 204,000 | 187,000 | 190,000 | 174,000 | |
| Deferred revenue, current portion | 842,000 | 541,000 | 657,000 | 693,000 | 1 | |
| Total current liabilities | 5 | 6 | 4 | 8 | 6 | |
| Operating lease liabilities | 209,000 | 398,000 | 596,000 | 830,000 | — | |
| Deferred revenue, net of current portion | 10,000 | 55,000 | 60,000 | 139,000 | 262,000 | |
| Total liabilities | 5 | 6 | 5 | 9 | 6 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, 5,000,000 shares authorized and none issued and outstanding | — | — | — | — | — | |
| Common stock, $0.01 par value 50,000,000 authorized; 17,056,845 issued and 16,463,809 outstanding at December 31, 2025; 17,036,845 issued and 16,495,396 outstanding at December 31, 2024 | 169,000 | 169,000 | 169,000 | 169,000 | 167,000 | |
| Additional paid-in capital | 46 | 46 | 45 | 45 | — | |
| Treasury stock, 593,036 and 541,449 shares at cost, at December 31, 2025 and December 31, 2024, respectively | −4 | −4 | −4 | −3 | −325,000 | |
| Retained earnings | 6 | 13 | 7 | 6 | −18 | |
| Total stockholders equity | 48 | 56 | 49 | 48 | 26 | |
| Total liabilities and stockholders equity | 53 | 62 | 54 | 57 | 32 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Credit loss expense | 44,000 | 123,000 | 7,000 | 145,000 | 78,000 | |
| Depreciation | 386,000 | 239,000 | — | — | — | |
| Amortization of right-of-use asset | 240,000 | 193,000 | 186,000 | 194,000 | — | |
| Provision for product warranties | 503,000 | 255,000 | 603,000 | 722,000 | 530,000 | |
| Stock-based compensation | 295,000 | 323,000 | 328,000 | 187,000 | 415,000 | |
| Deferred income taxes | −2 | −57,000 | −427,000 | −2 | — | |
| Accounts receivable | 14 | −9 | 7 | −5 | — | |
| Inventories | −5 | 268,000 | −9 | −3 | 3 | |
| Prepaid inventory | 2 | −361,000 | 3 | −5 | — | |
| Other current assets | −176,000 | −619,000 | −228,000 | 711,000 | — | |
| Other noncurrent assets | 12,000 | 152,000 | −312,000 | −417,000 | — | |
| Accounts payable and accrued expenses | −1 | 2 | −3 | 799,000 | 962,000 | |
| Operating lease liability | −242,000 | −181,000 | −201,000 | −199,000 | — | |
| Income tax payable | — | −37,000 | −853,000 | 890,000 | — | |
| Deferred revenue | 256,000 | −121,000 | −115,000 | −602,000 | −637,000 | |
| Product warranties | −557,000 | −464,000 | −468,000 | −827,000 | — | |
| Net cash provided by (used in) operating activities | 528,000 | −831,000 | −2 | −1 | −286,000 | |
| Acquisition of property and equipment | −196,000 | −276,000 | −229,000 | −159,000 | −128,000 | |
| Net cash used in investing activities | −196,000 | −276,000 | −187,000 | 15 | 129,000 | |
| Repurchase of common stock | −300,000 | — | −27,000 | −3 | — | |
| Withholding taxes on stock-based compensation | −5,000 | −52,000 | −59,000 | −109,000 | — | |
| Exercise of stock options | — | 67,000 | 46,000 | 731,000 | — | |
| Net cash (used in) provided by financing activities | −305,000 | 15,000 | −40,000 | −2 | −231,000 | |
| Net increase (decrease) in cash and cash equivalents | 27,000 | −1 | −2 | 11 | −388,000 | |
| Interest paid | — | — | — | 2,000 | 2,000 | |
| Income tax paid | 980,000 | 3 | 1 | 5 | — | |
| Income tax refunds received | 395,000 | — | — | — | — | |
| Net transfers from inventory to fixed assets | 169,000 | 1 | — | — | — | |
| Lease liability arising from obtaining right-of-use-assets | 111,000 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Sensus Healthcare, Inc.'s CIK number?
Sensus Healthcare, Inc.'s SEC CIK number is 0001494891 (1494891). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Sensus Healthcare, Inc.'s SEC filings?
All of Sensus Healthcare, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Sensus Healthcare, Inc. last report earnings?
Sensus Healthcare, Inc. (SRTS) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001753926-26-000782). This is Sensus Healthcare, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Sensus Healthcare, Inc.'s most recent earnings 8-K?
Sensus Healthcare, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001753926-26-000782. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Sensus Healthcare, Inc.'s latest earnings 8-K →
Look up any company's CIK number →